HIV evades RNA interference directed at TAR by an indirect compensatory mechanism.
暂无分享,去创建一个
Joshua N Leonard | David V Schaffer | Priya S Shah | J. Burnett | D. Schaffer | P. Shah | J. Leonard | John C Burnett
[1] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[2] Christopher D. Richardson,et al. Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region , 2005, Journal of Virology.
[3] G. Hutvagner,et al. A microRNA in a Multiple-Turnover RNAi Enzyme Complex , 2002, Science.
[4] M. Sioud,et al. Gene silencing in mammalian cells by preformed small RNA duplexes. , 2002, Biochemical and biophysical research communications.
[5] B. Berkhout,et al. Genetic Instability of Live, Attenuated Human Immunodeficiency Virus Type 1 Vaccine Strains , 1999, Journal of Virology.
[6] D. Baltimore,et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[7] Ben Berkhout,et al. Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition , 2004, Journal of Virology.
[8] P. Luciw,et al. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. , 1989, Genes & development.
[9] D. Baltimore,et al. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Carr. Toxicity of antiretroviral therapy and implications for drug development , 2003, Nature Reviews Drug Discovery.
[11] J. Rossi,et al. Rapid assessment of anti-HIV siRNA efficacy using PCR-derived Pol III shRNA cassettes. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] G. Nabel,et al. An inducible transcription factor activates expression of human immunodeficiency virus in T cells , 1990, Nature.
[13] Evaluating the binding affinities of NF-kappaB p50 homodimer to the wild-type and single-nucleotide mutant Ig-kappaB sites by the unimolecular dsDNA microarray. , 2003, Analytical biochemistry.
[14] J S Wall,et al. DNA looping and Sp1 multimer links: a mechanism for transcriptional synergism and enhancement. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Berro,et al. HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR , 2007, BMC Molecular Biology.
[16] J. Stone,et al. Poliovirus Escape from RNA Interference: Short Interfering RNA-Target Recognition and Implications for Therapeutic Approaches , 2005, Journal of Virology.
[17] D. Chen,et al. Transcription elongation factor P‐TEFb mediates Tat activation of HIV‐1 transcription at multiple stages , 1998, The EMBO journal.
[18] Joshua N. Leonard,et al. Computational Design of Antiviral RNA Interference Strategies That Resist Human Immunodeficiency Virus Escape , 2005, Journal of Virology.
[19] K. Crandall,et al. The causes and consequences of HIV evolution , 2004, Nature Reviews Genetics.
[20] T. Okamoto,et al. Transcriptional Repression of Human Immunodeficiency Virus Type 1 by AP-4* , 2006, Journal of Biological Chemistry.
[21] Stacy L DeRuiter,et al. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Wintersberger,et al. Histone Deacetylase 1 Can Repress Transcription by Binding to Sp1 , 1999, Molecular and Cellular Biology.
[23] Stefan L Ameres,et al. Molecular Basis for Target RNA Recognition and Cleavage by Human RISC , 2007, Cell.
[24] Michael T. McManus,et al. Gene silencing in mammals by small interfering RNAs , 2002, Nature Reviews Genetics.
[25] Ben Berkhout,et al. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome , 2005, Nucleic acids research.
[26] M. Horikoshi,et al. Repression of HIV-1 transcription by a cellular protein. , 1991, Science.
[27] R. Cheynier,et al. Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro , 1991, Journal of virology.
[28] A. Kimura,et al. Regulation of interaction of the acetyltransferase region of p300 and the DNA‐binding domain of Sp1 on and through DNA binding , 2000, Genes to cells : devoted to molecular & cellular mechanisms.
[29] Anastasia Khvorova,et al. Induction of the interferon response by siRNA is cell type- and duplex length-dependent. , 2006, RNA.
[30] J. S. Sullivan,et al. Genomic Structure of an Attenuated Quasi Species of HIV-1 from a Blood Transfusion Donor and Recipients , 1995, Science.
[31] N. Sonenberg,et al. A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. , 1990, Disease markers.
[32] Jared E. Toettcher,et al. Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity , 2005, Cell.
[33] B. Berkhout,et al. RNA interference against viruses: strike and counterstrike , 2007, Nature Biotechnology.
[34] B. Ramratnam,et al. Human Immunodeficiency Virus Type 1 Escape from RNA Interference , 2003, Journal of Virology.
[35] B. Berkhout,et al. Human Immunodeficiency Virus Type 1 Escape Is Restricted When Conserved Genome Sequences Are Targeted by RNA Interference , 2007, Journal of Virology.
[36] Ding‐Shinn Chen,et al. RNA interference-mediated control of hepatitis B virus and emergence of resistant mutant , 2005, Gastroenterology.
[37] M. Mathews,et al. Adenovirus virus-associated RNA and translation control , 1991, Journal of virology.
[38] J. Corbeil,et al. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[39] F. Clavel,et al. HIV Drug Resistance , 2000, The New England journal of medicine.
[40] D. Margolis,et al. Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production , 1994, Journal of virology.
[41] John J Rossi,et al. Genetic therapies against HIV , 2007, Nature Biotechnology.
[42] John J Rossi,et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[43] Andreas Meyerhans,et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.
[44] S. P. Walton,et al. Impact of target mRNA structure on siRNA silencing efficiency: A large‐scale study , 2008, Biotechnology and bioengineering.
[45] J. Rossi,et al. Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[46] D. Schaffer,et al. Selection of Novel Vesicular Stomatitis Virus Glycoprotein Variants from a Peptide Insertion Library for Enhanced Purification of Retroviral and Lentiviral Vectors , 2006, Journal of Virology.
[47] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[48] J. Leonard,et al. The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity , 1989, Journal of virology.
[49] Michael Zuker,et al. Mfold web server for nucleic acid folding and hybridization prediction , 2003, Nucleic Acids Res..
[50] K. Metzner,et al. Inhibition of drug-resistant HIV-1 by RNA interference. , 2006, Antiviral research.
[51] M. Stevenson,et al. Modulation of HIV-1 replication by RNA interference , 2002, Nature.
[52] K. Feldmann,et al. Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. , 1998, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology.
[53] E. Verdin,et al. NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation , 2006, The EMBO journal.
[54] Anne Gatignol,et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC , 2007, Nucleic acids research.
[55] Kazunari Taira,et al. Effects on RNAi of the tight structure, sequence and position of the targeted region. , 2004, Nucleic acids research.
[56] J. Rossi,et al. RNAi in Combination with a Ribozyme and TAR Decoy for Treatment of HIV Infection in Hematopoietic Cell Gene Therapy , 2006, Annals of the New York Academy of Sciences.
[57] R. Desrosiers,et al. Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.
[58] Ben Berkhout,et al. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] Paul Shinn,et al. HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.
[60] R. Desrosiers,et al. Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes. , 1994, AIDS research and human retroviruses.
[61] J. Lieberman,et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. , 2005, Blood.
[62] R. Harris,et al. The DNA Deaminase Activity of Human APOBEC3G Is Required for Ty1, MusD, and Human Immunodeficiency Virus Type 1 Restriction , 2008, Journal of Virology.
[63] Jin K. Wang,et al. Evaluating the binding affinities of NF-κB p50 homodimer to the wild-type and single-nucleotide mutant Ig-κB sites by the unimolecular dsDNA microarray , 2003 .
[64] Fred H. Gage,et al. Development of a Self-Inactivating Lentivirus Vector , 1998, Journal of Virology.
[65] J. Sodroski,et al. A second post-transcriptional trans-activator gene required for HTLV-III replication , 1986, Nature.